Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Several aspects on the use of portal vein embolization (PVE) are poorly studied and todays recommendations are based on low-grade evidence. In this Scandinavian multicenter cohort study we will study some of the controversial aspects on the use of PVE to try to provide clearer answers on its optimal use. Six tertiary university hospital hepatobiliary units in Sweden, Norway and Denmark participate and contribute with all PVE procedures performed at their units during the study period. We will then study several aspects PVE technique in relation to induced hypertrophy and surgical outcome.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| rPVE | Right portal vein embolization. All patients subjected to selective right portal vein embolization prior to planned hepatobiliary surgery. |
| |
| rPVE+S4 | Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Portal vein embolization | Procedure | Selective preoperative portal vein embolization |
|
| Measure | Description | Time Frame |
|---|---|---|
| Future liver remnant hypertrophy | Increase in future liver remnant, (%) | Based on radiology around 4 weeks before and after intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of segment 4 embolization on hypertrophy | Increase in future liver remnant (%) dependeing on if segment 4 is embolized or not. | Based on radiology around 4 weeks before and after intervention |
| Effect of hyperbilirubinemia on hypertrophy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Scandinavian patients subjected to PVE at 6 hepatobiliary centers during the study period.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ernesto Sparrelid, MD PhD | Contact | +46-708-880787 | ernesto.sparrelid@ki.se | |
| Stefan Gilg, MD PhD | Contact | +46-702-677722 | stefan.gilg@ki.se |
| Name | Affiliation | Role |
|---|---|---|
| Ernesto Sparrelid, MD PhD | Karolinska University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karolinska University Hospital | Recruiting | Stockholm | Sweden |
Data will be made available to other researchers on demand.
Data will be made available to other researchers on demand.
Data will be made available to other researchers on demand.
Not provided
Not provided
| ID | Term |
|---|---|
| D008113 | Liver Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Increase in future liver remnant (%) dependeing on the levels of bilirubin before portal vein embolization.
| Based on radiology around 4 weeks before and after intervention |
| Effect of sarcopenia on hypertrophy | Increase in future liver remnant (%) dependeing on the level of sarcopenia before portal vein embolization. | Based on radiology around 4 weeks before and after intervention |
| D008107 |
| Liver Diseases |